Larimar Therapeutics (LRMR) Competitors

$3.36 +0.13 (+3.86%)

As of 02:20 PM Eastern

LRMR vs. GLUE, AMLX, PAHC, IOVA, and ABCL

Should you buy Larimar Therapeutics stock or one of its competitors? MarketBeat compares Larimar Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Larimar Therapeutics include Monte Rosa Therapeutics (GLUE), Amylyx Pharmaceuticals (AMLX), Phibro Animal Health (PAHC), Iovance Biotherapeutics (IOVA), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry.

How does Larimar Therapeutics compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Larimar Therapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -302.69%. Monte Rosa Therapeutics' return on equity of -40.99% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%
Larimar Therapeutics	N/A	-134.14%	-96.00%

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 4.5% of Larimar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Monte Rosa Therapeutics presently has a consensus target price of $32.50, suggesting a potential upside of 81.76%. Larimar Therapeutics has a consensus target price of $16.33, suggesting a potential upside of 389.76%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

In the previous week, Larimar Therapeutics had 6 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 9 mentions for Larimar Therapeutics and 3 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.97 beat Larimar Therapeutics' score of 0.15 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monte Rosa Therapeutics has higher revenue and earnings than Larimar Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$42.95M	35.17	-$38.63M	-$1.48	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A

Monte Rosa Therapeutics has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Summary

Monte Rosa Therapeutics beats Larimar Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Larimar Therapeutics compare to Amylyx Pharmaceuticals?

Larimar Therapeutics (NASDAQ:LRMR) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Amylyx Pharmaceuticals' return on equity of -55.69% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

Larimar Therapeutics presently has a consensus price target of $16.33, suggesting a potential upside of 389.76%. Amylyx Pharmaceuticals has a consensus price target of $23.00, suggesting a potential upside of 80.18%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Larimar Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Larimar Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.11, suggesting that its stock price is 111% less volatile than the broader market.

Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
Amylyx Pharmaceuticals	N/A	N/A	-$144.74M	-$1.50	N/A

In the previous week, Amylyx Pharmaceuticals had 2 more articles in the media than Larimar Therapeutics. MarketBeat recorded 11 mentions for Amylyx Pharmaceuticals and 9 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.15 beat Amylyx Pharmaceuticals' score of -0.12 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amylyx Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by insiders. Comparatively, 12.3% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Amylyx Pharmaceuticals beats Larimar Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Larimar Therapeutics compare to Phibro Animal Health?

Larimar Therapeutics (NASDAQ:LRMR) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Phibro Animal Health has higher revenue and earnings than Larimar Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
Phibro Animal Health	$1.30B	1.06	$48.26M	$2.33	14.48

In the previous week, Larimar Therapeutics had 4 more articles in the media than Phibro Animal Health. MarketBeat recorded 9 mentions for Larimar Therapeutics and 5 mentions for Phibro Animal Health. Larimar Therapeutics' average media sentiment score of 0.15 beat Phibro Animal Health's score of 0.06 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phibro Animal Health	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Larimar Therapeutics currently has a consensus target price of $16.33, suggesting a potential upside of 389.76%. Phibro Animal Health has a consensus target price of $38.80, suggesting a potential upside of 14.98%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Larimar Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Larimar Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Phibro Animal Health has a net margin of 6.35% compared to Larimar Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
Phibro Animal Health	6.35%	37.14%	8.57%

Summary

Phibro Animal Health beats Larimar Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Larimar Therapeutics compare to Iovance Biotherapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Iovance Biotherapeutics (NASDAQ:IOVA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Larimar Therapeutics currently has a consensus price target of $16.33, suggesting a potential upside of 389.76%. Iovance Biotherapeutics has a consensus price target of $8.43, suggesting a potential upside of 143.25%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Larimar Therapeutics is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

In the previous week, Larimar Therapeutics had 7 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 9 mentions for Larimar Therapeutics and 2 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 0.67 beat Larimar Therapeutics' score of 0.15 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Iovance Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Larimar Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

Larimar Therapeutics has higher earnings, but lower revenue than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
Iovance Biotherapeutics	$263.50M	5.87	-$390.98M	-$0.95	N/A

Larimar Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. Iovance Biotherapeutics' return on equity of -50.17% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

Summary

Larimar Therapeutics beats Iovance Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Larimar Therapeutics compare to AbCellera Biologics?

Larimar Therapeutics (NASDAQ:LRMR) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

AbCellera Biologics has higher revenue and earnings than Larimar Therapeutics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
AbCellera Biologics	$75.13M	16.52	-$146.41M	-$0.48	N/A

Larimar Therapeutics presently has a consensus target price of $16.33, suggesting a potential upside of 389.76%. AbCellera Biologics has a consensus target price of $7.80, suggesting a potential upside of 91.88%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Larimar Therapeutics is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Larimar Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

Larimar Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market.

In the previous week, Larimar Therapeutics had 4 more articles in the media than AbCellera Biologics. MarketBeat recorded 9 mentions for Larimar Therapeutics and 5 mentions for AbCellera Biologics. Larimar Therapeutics' average media sentiment score of 0.15 beat AbCellera Biologics' score of -0.02 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbCellera Biologics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Larimar Therapeutics beats AbCellera Biologics on 9 of the 16 factors compared between the two stocks.

Get Larimar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LRMR vs. The Competition

Export

Metric	Larimar Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$346.44M	$2.98B	$6.28B	$12.14B
Dividend Yield	N/A	1.98%	2.80%	5.32%
P/E Ratio	-1.62	17.30	20.61	25.12
Price / Sales	N/A	576.86	581.13	92.21
Price / Cash	N/A	56.35	27.48	37.30
Price / Book	3.55	3.91	9.74	6.62
Net Income	-$165.67M	$74.99M	$3.55B	$335.39M
7 Day Performance	-19.25%	-4.48%	-1.79%	-1.72%
1 Month Performance	-30.52%	-8.02%	-3.65%	-1.61%
1 Year Performance	71.47%	29.92%	29.85%	27.79%

Larimar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LRMR Larimar Therapeutics	3.6415 of 5 stars	$3.37 +3.9%	$16.33 +385.4%	+63.6%	$349.56M	N/A	N/A	30	Earnings Report Analyst Upgrade Analyst Revision
GLUE Monte Rosa Therapeutics	2.8243 of 5 stars	$20.26 +4.5%	$32.50 +60.4%	+352.5%	$1.64B	$123.67M	N/A	90
AMLX Amylyx Pharmaceuticals	2.6935 of 5 stars	$14.88 +1.0%	$23.00 +54.6%	+165.7%	$1.64B	$87.37M	N/A	200
PAHC Phibro Animal Health	4.4213 of 5 stars	$36.32 -9.2%	$42.40 +16.7%	+42.4%	$1.62B	$1.30B	15.59	2,475	Gap Down High Trading Volume
IOVA Iovance Biotherapeutics	2.7618 of 5 stars	$3.70 +2.2%	$8.43 +127.8%	+104.2%	$1.62B	$263.50M	N/A	500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LRMR) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Larimar Therapeutics (LRMR) Competitors

LRMR vs. GLUE, AMLX, PAHC, IOVA, and ABCL

How does Larimar Therapeutics compare to Monte Rosa Therapeutics?

Summary

How does Larimar Therapeutics compare to Amylyx Pharmaceuticals?

Summary

How does Larimar Therapeutics compare to Phibro Animal Health?

Summary

How does Larimar Therapeutics compare to Iovance Biotherapeutics?

Summary

How does Larimar Therapeutics compare to AbCellera Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR vs. The Competition

Larimar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Larimar Therapeutics (LRMR) Competitors

LRMR vs. GLUE, AMLX, PAHC, IOVA, and ABCL

How does Larimar Therapeutics compare to Monte Rosa Therapeutics?

Is GLUE or LRMR more profitable?

Do institutionals and insiders believe in GLUE or LRMR?

Do analysts prefer GLUE or LRMR?

Does the media refer more to GLUE or LRMR?

Which has higher valuation and earnings, GLUE or LRMR?

Which has more volatility & risk, GLUE or LRMR?

Summary

How does Larimar Therapeutics compare to Amylyx Pharmaceuticals?

Is LRMR or AMLX more profitable?

Do analysts prefer LRMR or AMLX?

Which has more volatility and risk, LRMR or AMLX?

Which has better valuation and earnings, LRMR or AMLX?

Does the media prefer LRMR or AMLX?

Do institutionals & insiders hold more shares of LRMR or AMLX?

Summary

How does Larimar Therapeutics compare to Phibro Animal Health?

Which has higher earnings & valuation, LRMR or PAHC?

Does the media favor LRMR or PAHC?

Do institutionals and insiders hold more shares of LRMR or PAHC?

Do analysts prefer LRMR or PAHC?

Which has more risk & volatility, LRMR or PAHC?

Is LRMR or PAHC more profitable?

Summary

How does Larimar Therapeutics compare to Iovance Biotherapeutics?

Do analysts prefer LRMR or IOVA?

Does the media refer more to LRMR or IOVA?

Do institutionals & insiders hold more shares of LRMR or IOVA?

Which has more risk and volatility, LRMR or IOVA?

Which has higher valuation & earnings, LRMR or IOVA?

Is LRMR or IOVA more profitable?

Summary

How does Larimar Therapeutics compare to AbCellera Biologics?

Do insiders & institutionals hold more shares of LRMR or ABCL?

Which has preferable earnings and valuation, LRMR or ABCL?

Do analysts prefer LRMR or ABCL?

Is LRMR or ABCL more profitable?

Which has more risk & volatility, LRMR or ABCL?

Does the media prefer LRMR or ABCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR vs. The Competition

Larimar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools